Association Between Plasma Level of Mannose Binding Lectin and Human Reproduction

Sponsor
Aalborg University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05169541
Collaborator
(none)
500
1
9.9
50.6

Study Details

Study Description

Brief Summary

A low plasma level of mannose binding lectin (p-MBL) is associated with unexplained recurrent pregnancy loss (RPL), but it is not investigated if it is associated with unexplained reproductive failure in general, including recurrent implantation failure (RIF) after assisted reproductive technology (ART) (including IVF, ICSI and FET), recurrent pregnancy loss (RPL) after spontaneous conception, and RPL after ART.

Detailed Description

The prevalence of a low p-MBL level is higher in patients with unexplained RPL than in the background population, while a high level is significantly less frequent in RPL patients (Nørgaard-Pedersen et al., submitted).

Approximately 50% of RPL patients have none of the evidence-based risk factors associated with RPL. Unexplained RPL is more complicated since finding the cause is essential for offering the optimal intervention to improve the patient's chances of a child.

Other conditions characterized by reproductive failure are infertility and recurrent implantation failure (RIF). The underlying mechanisms and the physiologic stage in early pregnancy being complicated and impeding normal pregnancy may probably differ between these pathologic conditions, since theoretically RIF would involve complicated embryo apposition, adhesion and invasion and clinical/visualized pregnancy losses would involve complicated stages later in the implantation process and fetal development. However, these conditions are suggested to have partly overlapping causes since most of the evidence-based risk factor recur; including parental chromosomal abnormalities, and maternal endocrine disorders, acquired thrombophilia, anatomic abnormalities in the uterine cavity, and endometrial and ovarian diseases. In addition, adverse immune responses against the embryo have been suggested as a cause of reproductive failure. If RPL is associated with a low p-MBL level, RIF may be so too.

The investigators aim to explore the p-MBL level in patients suffering from reproductive failure.

If low p-MBL level is associated with all the investigated subgroups of patients suffering from reproductive failure, this would strengthen our theory that MBL is involved in the pathophysiology characterized by reproductive failure in the very early stages of pregnancy and should therefore take part in the exploration of all patients with reproductive failure.

Study Design

Study Type:
Observational
Anticipated Enrollment :
500 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Is Plasma Level of Mannose Binding Lectin Associated With Reproductive Failure?
Actual Study Start Date :
Feb 2, 2022
Anticipated Primary Completion Date :
Nov 30, 2022
Anticipated Study Completion Date :
Nov 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Recurrent pregnancy loss after spontaneous conception

Minimum three consecutive losses from pregnancies achieved after spontaneous conception

Recurrent pregnancy loss after assisted reproductive treatment

Minimum three consecutive losses from pregnancies achieved after assisted reproductive treatment (ART), which includes in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and frozen embryo transfer (FER).

Recurrent implantation failure

Minimum three consecutive embryo transfers (ET) of good quality embryos with no hCG production. The patient must not have experienced any clinical pregnancies (i.e. evidence of pregnancy on an US or by histopathological examination) after IVF or spontaneous conception. Biochemical pregnancies after spontaneous conception, which terminated before evidence of a gestational sac on an ultrasonic scan (US) could be visualized and before the series of RIF occurred, are accepted.

Outcome Measures

Primary Outcome Measures

  1. Low p-MBL level [Blood sample collected after admission when the patient is not pregnant or <9 weeks of gestation.]

    Low plasma mannose binding lectin level defined as <500 ug/l

  2. Very low p-MBL level [Blood sample collected after admission when the patient is not pregnant or <9 weeks of gestation.]

    Very low plasma mannose binding lectin level defined as <100 ug/l

  3. High p-MBL level [Blood sample collected after admission when the patient is not pregnant or <9 weeks of gestation.]

    High plasma mannose binding lectin level defined as >3000 ug/l

Secondary Outcome Measures

  1. Odds ratio for a low p-MBL level [Blood sample collected after admission when the patient is not pregnant or <9 weeks of gestation.]

    Comparing prevalence in the patient group with danish female background population (n=185)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 41 Years
Sexes Eligible for Study:
Female
Inclusion Criteria:

fulfil one of the following:

  • 3 consecutive pregnancy losses after spontaneous conception

  • 3 consecutive pregnancy losses after assisted reproductive technology treatment (ART) including IVF, ICSI and FET

  • 3 failed embryo transfers characterized by no achieved pregnancy (after 3 cycles with minimum 1 embryo transfer of a good-quality embryo in each cycle.)

Exclusion Criteria:
  • Age <18 or >45 years

  • AMH <4.0 pmol/l unless donor egg in previous cycles

  • Significant uterine malformation

  • Known endometrial pathologies including intrauterine endometriosis, adenomyosis, hyperplasia or polyps

  • Known chromosomal abnormalities

  • Pregnancy >9 weeks of gestation at the time collecting the blood sample

Contacts and Locations

Locations

Site City State Country Postal Code
1 Aagaard Klinik Aarhus Denmark 8200

Sponsors and Collaborators

  • Aalborg University Hospital

Investigators

  • Principal Investigator: Caroline Nørgaard-Pedersen, M.D., Aalborg University Hospital, Denmark

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Caroline Nørgaard-Pedersen, Principal investigator, Aalborg University Hospital
ClinicalTrials.gov Identifier:
NCT05169541
Other Study ID Numbers:
  • MBL_reproduction_2022
First Posted:
Dec 27, 2021
Last Update Posted:
Feb 3, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 3, 2022